Additional Relevant Details Thermo Fisher Scientific Inc., (NYSE: TMO), the world leader in serving science, and Groupe Novasep SAS (Novasep), a leading supplier of services and technologies for the life sciences industry, today announced that Thermo Fisher has completed the acquisition of Henogen S.A., Novasep's viral vector manufacturing business in Belgium for approximately €725 million in cash.
Novasep's viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. With two locations in Seneffe and Gosselies, Belgium, Novasep's viral vector business offers more than 7,000 square meters of state-of-the-art clinical and commercial manufacturing capacity. Founded more than 20 years ago, the business has approximately 400 employees with substantial operational and technical expertise in a broad range of viral vector classes and estimated 2020 revenue of €80 million (or approximately $95 million).